Eosinophilic esophagitis (EoE) is characterized by infi ltration of eosinophils into esophageal epithelium. Blood levels of an eosinophil granule protein, eosinophil-derived neurotoxin (EDN), have been proposed as a biomarker for EoE. However, information regarding localization of EDN in the diseased tissues has not been available. The goal of this study was to evaluate the magnitude and distribution of EDN deposition in tissue specimens from the esophagus of EoE patients.
INTRODUCTION
Eosinophilic esophagitis (EoE) is a clinicopathologic disease characterized by intense eosinophilic infi ltration in the esophageal epithelium, upper gastrointestinal symptoms (dysphagia, food impaction, feeding intolerance, heartburn, etc), and lack of responsiveness to treatment with high-dose proton pump inhibitors (1 -3) . Although the role of eosinophils in the pathophysiology of EoE is not fully understood, intense eosinophil infi ltration of the esophageal epithelium has been used as a diagnostic hallmark of EoE. Th e minimum number of eosinophils required to diagnose EoE typically ranges from ≥ 15 to ≥ 30 in one or more high-power fi elds (HPFs) as seen by hematoxylin and eosin (H & E) staining (2, 4, 5) . Recently, a consensus group proposed a diagnostic guideline of ≥ 15 eosinophils in one HPF (2) . Despite this consensus statement, there seems to be no universal agreement in the medical literature on either the number of eosinophils required to diagnose EoE, the area of the HPF, or the location and number of biopsies used to generate that number (6, 7) . In addition, EoE
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is reportedly a patchy disease with variations in both numbers of eosinophils and histological fi ndings. Among biopsy specimens taken from the same site and even within a given biopsy, the number of eosinophils can vary widely (4) , creating a challenge for the accurate diagnosis of EoE.
Eosinophil granules contain several cytotoxic proteins, including eosinophil-derived neurotoxin (EDN). Cellular activation with appropriate stimuli leads to extracellular release of the granule proteins (8) , and extracellular EDN has been used as an indicator of eosinophil activation and degranulation in vitro (9) . Clinically, increased levels of EDN in body fl uids have been observed in patients with various eosinophil-associated diseases. For example, in children with asthma, EDN levels are elevated in serum and urine (10) . In patients with infl ammatory bowel disease, EDN levels in whole gut lavage fl uids may be a more stable marker of eosinophil degranulation than eosinophil major basic protein (MBP) levels (11) . A recent EoE study showed that plasma EDN levels correlate with esophageal eosinophil density (12) . Furthermore, plasma EDN levels have been proposed as a noninvasive biomarker for diagnosing or monitoring EoE (2, 12) . Surprisingly, there were no diff erences in fecal EDN levels in EoE patients compared with unaff ected controls (12) , raising fundamental questions as to whether EDN is present or released in the digestive tracts of patients with active EoE. No previous reports have examined the presence of EDN in esophageal tissues from EoE patients or characterized the magnitude and distribution of EDN deposition among them.
Th erefore, we examined esophageal biopsy specimens from EoE patients and histologically normal controls for EDN by immunofl uorescence. In the majority of EoE patients, we found marked deposition of extracellular EDN; in histologically normal controls, EDN staining was minimal or absent. Importantly, specimens from some EoE patients showed marked extracellular EDN deposition despite relatively small numbers of intact eosinophils. Th us, in certain EoE patients, the number of eosinophils in esophageal specimens may underestimate the magnitude of eosinophil involvement in their esophageal pathology.
METHODS

Study population
Four mid-esophageal biopsies (10 -15 cm above the gastroesophageal border) were obtained from 10 patients with EoE and embedded in one paraffi n block. Th eir mean age was 41 (29 -49) years, and nine were male. Inclusion criteria were: >17 years of age, ≥ 20 eosinophils / HPF (vide infra), and dysphagia. Each patient completed a validated dysphagia questionnaire (13) . Th is study was performed before the consensus defi nition (2) of EoE requiring a normal pH monitoring study of the distal esophagus and failure of symptoms to respond to PPI therapy was established. Th erefore, we used the criterion of ≥ 20 eosinophils / HPF (maximum density) to minimize the possibility of including patients with gastroesophageal refl ux disease (GERD). Exclusion criteria were: systemic or topical steroid use in the past 3 months, previous dietary or pharmacological therapy for EoE, erosive esophagitis, and dilatation of esophagus at the time of index endoscopy.
One section from the paraffi n block of each patient was stained with H & E and read by a GI pathologist (TS). Th e area of greatest eosinophil density within the four biopsies was located by low-power review. Th en, within this area, eosinophils were counted in the one HPF containing the greatest density of eosinophils, using a Nikon E600 microscope with a × 40 objective fi eld diameter of 0.6 mm and a fi eld area of 0.31 mm 2 ( Table 1 ) . Th e mean number of eosinophils / HPF (maximum density) for the 10 EoE patients was 53 (range 25 -100). Five patients had a PPI trial that did not resolve their dysphagia symptoms. All patients had solid food dysphagia that subsequently responded to topical steroid therapy. Th ree of the patients had heartburn. Endoscopic fi ndings of EoE (rings, furrows, or white spots) were seen in 7 patients. None of the patients had esophageal strictures (endoscopically seen narrowing of >4 mm).
In addition, mid-esophageal biopsy specimens were obtained from eight histologically normal controls; their mean age was 39 (10 -70) years, three were under age 17, and four were male. Four controls had dysphagia, and fi ve controls had heartburn or regurgitation symptoms. Th ese biopsy specimens were histologically normal, that is, no pathological abnormalities were present on H & E-stained sections, and no eosinophils were present. All controls had a normal endoscopy.
Immunofl uorescence staining of tissue specimens
Serial sections from the mid-esophageal specimen of each patient and control were examined by immunofl uorescence to detect EDN or major basic protein (MBP) as described previously (14 -18) . Briefl y, sections were deparaffi nized, rehydrated, incubated with 0.1 % trypsin (Sigma, St. Louis, MO) to expose antigenic sites, and blocked overnight in 10 % normal goat serum (Pel-Freez Biologicals, Rogers, AR). Aft er washing the next day, the slides were incubated with either polyclonal rabbit anti-human EDN, or affi nity-purifi ed polyclonal rabbit anti-human MBP (both prepared at Mayo Clinic Rochester), or normal rabbit serum (NRS) (Pel Freez) as a control. Th e slides were then washed and incubated in 1 % chromotrope 2R (Sigma) to block nonspecifi c staining of eosinophils by the fl uorescein-labeled secondary antibody. Th e slides were washed again and incubated with fl uorescein-labeled goat anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA). Aft er a fi nal wash, the slides were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), coverslipped, and sealed.
Specifi city of EDN antibody
Th e specifi city of the EDN antibody was examined by a series of immunoabsorption experiments. EDN protein and human serum albumin (HSA, Sigma) were coupled to cyanogen bromide-activated Sepharose 4B (Sigma) as previously described (19) . Briefl y, 2 mg of each protein was ESOPHAGUS Kephart et al.
added to 2 ml activated Sepharose and rotated for 24 h at 4 ° C. An additional 2 ml aliquot of activated Sepharose with no protein was rotated similarly. Th e remaining active sites were blocked with lysine monohydrochloride, and ionically bound protein was removed by alternating washes of acetate buff er (pH = 4) and coupling buff er (pH = 8). Two ml of a 1:10 dilution of the EDN antibody was added to each protein-coupled Sepharose and uncoupled Sepharose and rotated as above. Th e resulting supernatants were tested by immunofl uorescence on sections from two EoE patient biopsy specimens at a 1:80 dilution, the same dilution used for the unabsorbed EDN antibody.
Analysis of specimens
Th e immunofl uorescent-stained slides were examined at × 160 (Zeiss × 16 objective, fi eld diameter = 1.5 mm) with an Axiophot fl uorescence microscope (Carl Zeiss, Oberkochen, Germany), equipped with an AxioCam HRc digital camera and Axio Vision 4.2 soft ware. By using a × 16 objective, we examined an area nearly six-fold larger (1.76 mm 2 ) than that encompassed with a Nikon × 40 objective (0.31 mm 2 ). We evaluated the two largest biopsies in the paraffi n block from each patient and control because these biopsies would have the least amount of crush artifact, if any. To evaluate the amount of EDN staining in the specimens objectively EDN, eosinophil-derived neurotoxin; EoE, eosinophilic esophagitis; HPF, high-power fi eld; n / a, specimens not available. a Each mid-esophageal specimen was independently graded using a 7-point scale (0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0) by two observers, and their results were averaged. For example, for eosinophil infi ltration for EoE patient 4, the two observers ' scores for biopsy no. 1 were 1.5 and 1.0 with a mean of 1.3. Likewise, for biopsy no. 2, the scores were 1.0 and 1.0 with a mean of 1.0. These two means were averaged to obtain an overall score for eosinophil infi ltration in EoE patient 4 of 1.2. The other average scores were calculated similarly.
b Maximum number of eosinophils in one × 400 intraepithelial fi eld on hematoxylin and eosin -stained section.
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and reproducibly, a scoring system similar to that used for MBP staining in stomach and small bowel endoscopic biopsy specimens (20) was developed. Representative photomicrographs ( × 160) were taken to document the spectra of eosinophil infi ltration and extracellular EDN deposition in esophageal biopsy specimens. Photomicrographs that illustrated degrees of either primarily eosinophil infi ltration or primarily extracellular EDN deposition were selected and assigned scores of 0 (none), 1 (minimal), 2 (moderate), and 3 (confl uent); these photographs became the standards used in the scoring procedure ( Figure 5 , vide infra). Using these scoring standards and a × 16 objective, we evaluated cellular EDN staining (i.e., eosinophil infi ltration) in the biopsies on a 7-point scale from 0 -3 in increments of 0.5; extracellular EDN staining (i.e., deposition of released EDN) was scored similarly. To obtain mean scores for eosinophil infi ltration and extracellular EDN deposition, the two largest biopsies from each paraffi n block were scored independently by two investigators (GMK and HK) who were unaware of the diagnosis. Th e investigators ' scores for the two biopsies from each patient were averaged, and an overall mean value was calculated (see footnote in Table 1 for an example of the calculations).
Statistical analysis
Correlation between the eosinophil infi ltration scores and extracellular EDN deposition scores was analyzed by Spearman rank, using a statistical soft ware package (Instat 3.0, GraphPad Soft ware Abacus Concepts, La Jolla, CA).
RESULTS
Deposition of EDN is more pronounced than MBP in EoE patient biopsy specimens
In studies of asthma and atopic dermatitis, MBP has been used as a marker of eosinophil infi ltration and degranulation (15, 21) . Th erefore, we compared MBP and EDN staining in serial sections of an esophageal biopsy specimen from an EoE patient. Although the patterns of the cellular EDN ( Figure 1a ) and MBP ( Figure 1b ) staining were roughly similar, the patterns of the extracellular staining were strikingly diff erent. Th e extracellular MBP staining was largely granular, whereas the extracellular EDN deposition was diff use and covered a larger area compared with the extracellular MBP staining. Serial sections were stained with H & E ( Figure 1c ) and NRS ( Figure 1d ) ; the NRS-stained section was negative. A specimen from another EoE patient showed similar fi ndings.
To verify the specifi city of EDN staining, we performed a series of immunoabsorption studies. Absorption of EDN antibody with either uncoupled Sepharose or HSA-Sepharose did not aff ect the immunoreactivity, as EoE patient biopsy sections stained with these absorbed antibodies showed staining similar to that of the unabsorbed EDN antibody. In contrast, absorption of EDN antibody with EDN-Sepharose completely removed the immunoreactivity; weak fl uorescence from what appears to be autofl uorescence of red blood cells was the only signal detectable (see Supplementary Figures 1 and 2 online) . Th ese results, along with data showing the purity of the EDN used to immunize the rabbits, show that the anti-EDN antibody is specifi c for EDN (22) . Th erefore, we examined the use Figure 3h ). Serial sections to those shown in Figure 3c and e were stained with NRS plus FITC-conjugated goat anti-rabbit IgG and showed no visible fl uorescence signal (see Supplementary Figure 3 online). Furthermore, consistent with the patchy nature of EoE histology, heterogeneous EDN staining was seen not only among diff erent biopsies taken from the same site, but also within the same biopsy. For example, within a given biopsy, a few eosinophils and minimal extracellular deposition could be present in one × 160 fi eld ( Figure 4a ), whereas extensive extracellular EDN deposition could be present in an adjacent × 160 fi eld ( Figure 4b ).
Scoring of intracellular and extracellular EDN staining
Th us, all EoE biopsy specimens showed EDN staining; however, the pattern and the distribution of the EDN staining among the EoE patients were heterogeneous. Th erefore, to evaluate the deposition of EDN systematically and objectively, of EDN as a marker of eosinophil involvement in esophageal biopsy specimens from 10 EoE patients and eight histologically normal controls.
EoE patients ' biopsy specimens show marked EDN deposition with three distinct patterns
Esophageal biopsy specimens from histologically normal controls showed very few or no intact eosinophils; likewise, extracellular EDN deposition was minimal ( Figures 2a -f ). In contrast, biopsy specimens from EoE patients showed marked cellular and extracellular EDN staining ( Figure 3 ). Th ree different patterns of EDN staining were observed in EoE patients: primarily cell-associated, a combination of cell-associated and extracellular EDN deposition, and primarily extracellular EDN deposition. For example, specimens from 2 / 10 patients showed primarily eosinophil infi ltration with minimal extracellular EDN deposition ( Figures 3a and b ). Figure 3b is an H & E counterstain of Figure 3a and illustrates that the cells staining with the EDN antibody are eosinophils (white and black arrows). Biopsy specimens from 6 / 10 patients showed both eosinophil infi ltration and extracellular EDN deposition ( Figures 3c and d ) . Interestingly, biopsy specimens from 2 / 10 patients showed widespread diff use extracellular EDN deposition with minimal eosinophil infi ltration ( Figures  3e -h ). Diff use extracellular EDN deposition was oft en seen that represented the various magnitudes (Grade 1, minimal; Grade 2, moderate; and Grade 3, confl uent) of both cellular and extracellular EDN deposition. By comparison to these standards, two observers examined the two largest biopsies of each mid-esophageal specimen and assigned scores for both eosinophil infi ltration (intracellular EDN) and extracellular EDN deposition. Th e scores of the two observers were averaged to obtain a mean score for each biopsy (e.g., Biopsy no. 1 and Biopsy no. 2), and the scores from the two biopsies were averaged to obtain overall scores for eosinophil infi ltration and extracellular EDN deposition for each mid-esophageal specimen.
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In the biopsy specimens from histologically normal controls, scores for both eosinophil infi ltration and extracellular EDN deposition were u 0.5 in all specimens ( Table 1 ). In contrast, in the EoE patients, marked eosinophil infi ltration and / or abundant extracellular EDN deposition were evident with mean scores of 1.8 and 2.1, respectively ( Table 1 ). Biopsy specimens we developed a scoring system ( Figure 5 ) to analyze semiquantitatively the amount of EDN staining. Th e scoring system was based on standards ( × 160 photomicrographs) . Correlation between eosinophil infi ltration scores and extracellular eosinophil-derived neurotoxin (EDN) deposition scores in eosinophilic esophagitis patients. Each dot represents a mean score from two independent observers for each biopsy. 
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Eosinophil-Derived Neurotoxin in EoE from 6 / 10 EoE patients had mean scores of 1.5 for both cellular and extracellular EDN staining. In contrast, biopsy specimens from 2 / 10 EoE patients (patients 1 and 8) showed primarily intact eosinophil infi ltration (mean scores of 2.3 and 1.8, respectively) and minimal extracellular EDN deposition (mean scores of 1.0). Biopsy specimens from another 2 / 10 EoE patients (patients 4 and 10) showed extracellular EDN deposition (mean scores of 2.3 and 2.5, respectively) and only minimal eosinophil infi ltration (mean scores of 1.2 and 1.3, respectively). Figure 6 shows a comparison between eosinophil infi ltration scores and extracellular EDN deposition scores of all EoE patient biopsy specimens. Overall, there was no correlation between eosinophil infi ltration and extracellular EDN deposition (R = − 0.0067, P = 0.9790).
DISCUSSION
Development of sensitive and reliable biomarkers for EoE is critical for the diagnosis and management of EoE patients and for patients enrolled in clinical trials of EoE. Plasma EDN levels correlate with esophageal eosinophil counts and have been proposed as a noninvasive biomarker for diagnosing or monitoring EoE (2, 12) . However, there were no differences in fecal EDN levels in EoE patients compared with normal controls (12) . In this study, we stained esophageal biopsy specimens from EoE patients for EDN by immunofluorescence to evaluate the magnitude and distribution of both eosinophil infiltration and extracellular EDN deposition. No or minimal EDN staining (mean scores of u 0.5 for both cellular and extracellular deposition) was found in esophageal biopsy specimens from histologically normal controls, consistent with previous observations that eosinophils are not present in the normal esophagus (23, 24) . In contrast, eosinophil infi ltration and extracellular EDN deposition were regularly seen in EoE patients. Importantly, the extent of extracellular EDN deposition did not correlate with the number of infi ltrating eosinophils ( Figures 3 and 6 ). For example, marked eosinophil infi ltration was observed with minimal extracellular EDN deposition ( Figure 3a and b ) , whereas in others, marked extracellular EDN deposition was observed with relatively small numbers of intact eosinophils ( Figure 3e and f ) . Furthermore, both eosinophil infi ltration and extracellular EDN deposition were heterogeneous even within a given specimen ( Figure 4 ). Previously, a study of skin biopsy specimens from patients with atopic dermatitis showed deposition of eosinophil granule proteins in the dermis in the virtual absence of intact eosinophils (21) . Th us, using a given number of intact eosinophils in an H & E-stained section as a diagnostic cutoff could underestimate the extent of eosinophil infl ammation. More comprehensive approaches to analyze both the numbers of infi ltrating eosinophils as well as the magnitude of deposition of eosinophil-derived products (e.g., EDN) may be necessary to diagnose EoE accurately.
Th e reason(s) for more marked eosinophil degranulation in the esophagus of some EoE patients but not in others is unknown. Receptors for cytokines, chemokines, complement, immunoglobulins, and proteases allow eosinophils to interact with the extracellular milieu (25) . In particular, Th 2 cytokines, such as IL-5 and IL-13, and eotaxin-3 are implicated in the pathophysiology of EoE (3) ; in vitro exposure of eosinophils to these cytokines / chemokines induces degranulation (8) . Furthermore, systemic expression of IL-5 and epithelial expression of eotaxin-2 induced extensive eosinophil degranulation as well as structural damage and remodeling in mouse airways in vivo (26) . In addition, when EoE patients were treated with anti-IL-5 antibody (mepolizumab), both blood eosinophil numbers and cell activation decreased (27) . Th us, eosinophil degranulation and the subsequent deposition of EDN in the esophagus may refl ect tissue levels of IL-5 and eotaxin and may represent a useful marker for the immunological disease activity of EoE.
Once released extracellularly, EDN could activate human dendritic cells, with subsequent production of infl ammatory mediators (28) . In mice, EDN can stimulate dendritic cell maturation through the TLR2-signaling pathway and enhance antigen-specifi c Th 2 immune responses, suggesting that EDN may act as an alarmin (29, 30) . Furthermore, EDN can be toxic to certain mammalian cells (31) . Although MBP and EDN are both presumably products of eosinophil degranulation, we also found distinctive diff erences between EDN and MBP staining ( Figure 1 ). Although the reasons for this observation are unknown, the biochemical diff erences between MBP and EDN might provide an explanation. MBP is a highly basic and amphipathic protein; it readily precipitates at neutral pH (32) . In contrast, the isoelectric point of EDN is closer to neutral, and it does not readily precipitate from neutral solutions. Th erefore, once released from eosinophils, EDN may diff use further into the tissues than MBP. Another possibility is the so-called " diff erential degranulation of eosinophils " mechanism; under certain experimental conditions, eosinophils appear to release one granule protein but not another (33) . A similar mechanism may occur in vivo in patients with EoE. Further studies are needed to elucidate the mechanisms for EDN release by eosinophils in esophageal mucosa and to investigate the role of released EDN in the pathophysiology of EoE.
We recognize several limitations in this study. Th e sample size is small. Th e EoE patients and histologically normal controls are not matched for sex, age, or medications. However, our observations of minimal or no EDN staining in esophageal specimens from histologically normal controls are consistent with previous fi ndings that indicate few or no eosinophils are present in normal esophageal mucosa (23, 24) . Furthermore, we studied specimens from only one esophageal site (mid-esophagus) from each patient and control. Using the criterion of 15 eosinophils / HPF, Gonsalves et al. (34) showed that fi ve biopsies are needed to obtain a diagnostic sensitivity of 100 % for EoE. Given the heterogeneous nature of the eosinophil distribution in EoE, a recent review article recommended obtaining four biopsy specimens from both the proximal and the distal esophagus to maximize diagnostic sensitivity (35) . Finally, as mentioned in the Methods section, this study was performed before the consensus defi nition of EoE was established. Th erefore, our study may have included patients with GERD. However, all patients had topical steroid-responsive dysphagia, most had typical endoscopic fi ndings of EoE, and half (including all those with heartburn or regurgitation symptoms) had a PPI trial without relief of their dysphagia.
In conclusion, we found that localization of EDN may be a useful biomarker of eosinophilic infl ammation in esophageal tissues from EoE patients. Rather than counting eosinophils by H & E staining, could evaluation of EDN staining (which detects both eosinophil infi ltration and degranulation and assesses a larger area of an esophageal biopsy specimen) reduce the number of biopsy specimens nece ssary to make an accurate diagnosis of EoE? Alternatively, would EDN deposition in esophageal tissues better refl ect the extent of immunological disease in EoE than eosinophil numbers determined by H & E staining? Further studies of EDN staining in patients with both minimal eosinophilia on H & E staining and clinical symptoms of EoE and in those patients with GERD are needed to evaluate the potential utility of EDN staining to diagnose patients whose disease status is presently ambiguous.
